Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Oak Ridge Investments LLC

Oak Ridge Investments LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,908 shares of the pharmaceutical company’s stock after acquiring an additional 81 shares during the period. Oak Ridge Investments LLC’s holdings in Vertex Pharmaceuticals were worth $768,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in VRTX. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter worth $25,000. Highline Wealth Partners LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at $27,000. Dunhill Financial LLC grew its position in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at about $35,000. 90.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on VRTX shares. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their price target on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Finally, Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.2 %

NASDAQ VRTX opened at $422.00 on Monday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm’s fifty day simple moving average is $440.94 and its 200-day simple moving average is $466.09. The company has a market capitalization of $108.68 billion, a PE ratio of -212.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period in the previous year, the company earned $3.67 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.